ArticleThe Journal of clinical investigation2009
Preventing and exploiting the oncogenic potential of integrating gene vectors.
Article in The Journal of clinical investigation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- [Research progresses in gene therapy for hepatolenticular degeneration].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
- Immunotherapy against colorectal cancer via delivery of anti-PD-L1 nanobody mRNA.eGastroenterology · 2025Article
- Novel Programmed Death Ligand 1-AKT-engineered Mesenchymal Stem Cells Promote Neuroplasticity to Target Stroke Therapy.Molecular neurobiology · 2024Article
- Challenges of Gene Editing Therapies for Genodermatoses.International journal of molecular sciences · 2023Review
- Infectious Causes of Neoplasia in the Domestic Cat.Veterinary sciences · 2022Review
- A review of the underlying genetics and emerging therapies for canine cardiomyopathies.Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology · 2022Review
- Gene Therapy: A Possible Alternative to CFTR Modulators?Frontiers in pharmacology · 2021Article
- mRNA as novel technology for passive immunotherapy.Cellular and molecular life sciences : CMLS · 2019Review
- Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework.Frontiers in medicine · 2017Review
- Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage.Current neuropharmacology · 2016Review
- [Advances of lentiviral vectors].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2014Review
- Transduction of fetal mice with a feline lentiviral vector induces liver tumors which exhibit an E2F activation signature.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- In vivo reprogramming for heart disease.Cell research · 2012Article
- Nucleic Acid-Based Therapy Approaches for Huntington's Disease.Neurology research international · 2012Article
- Regenerative medicine and the gut.Gastroenterology · 2011Review
- Immunization delivered by lentiviral vectors for cancer and infectious diseases.Immunological reviews · 2011Review
- Challenges with advanced therapy medicinal products and how to meet them.Nature reviews. Drug discovery · 2010Review
- Versatile somatic gene transfer for modeling neurodegenerative diseases.Neurotoxicity research · 2009Review
- Towards a clinically relevant lentiviral transduction protocol for primary human CD34 hematopoietic stem/progenitor cells.PloS one · 2009Article
- Chromatin tethering and retroviral integration: recent discoveries and parallels with DNA viruses.Biochimica et biophysica actaReview
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
Gene therapy requires efficient gene delivery to cure or prevent disease by modifying the genome of somatic cells. However, gene vectors, which insert themselves into the host genome in order to achieve persistent protein expression, can trigger oncogenesis by upregulating cellular protooncogenes. This adverse event, known as insertional mutagenesis, has become a major hurdle in the field. Vectors developed on the basis of lentiviruses are considered to be less genotoxic than the hitherto used gamma-retroviral vectors. For their report in this issue of the JCI, Montini et al. utilized a tumor-prone mouse model to identify the genetic determinants of insertional mutagenesis (see the related article beginning on page 964). They report that the lentiviral integration pattern and additional improvements in vector design reduce the genotoxic risk. These findings will inform future vector design with the goal of limiting genotoxicity for gene therapy or increasing genotoxicity for protooncogene discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.